The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

A new study shows weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, yield lower weight reductions in ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting drug it has developed to create a new standard of patient care for weight ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.